SHR3824, a novel selective inhibitor of renal sodium glucose cotransporter 2, exhibits antidiabetic efficacy in rodent models

• Published in: Acta pharmacologica Sinica Vol. 35; no. 5; pp. 613 - 624
• Main Authors: Yan, Pang-ke, Zhang, Li-na, Feng, Ying, Qu, Hui, Qin, Li, Zhang, Lian-shan, Leng, Ying
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.05.2014; Nature Publishing Group
• Subjects: Animals; Biomedical and Life Sciences; Biomedicine; Blood Glucose - drug effects; Blood Glucose - metabolism; Diabetes Mellitus, Experimental - drug therapy; Diabetes Mellitus, Experimental - metabolism; Glucose - metabolism; HEK293 Cells; Humans; Hyperglycemia - drug therapy; Hyperglycemia - metabolism; Hypoglycemic Agents - pharmacology; Immunology; Insulin - metabolism; Insulin Resistance; Insulin-Secreting Cells - drug effects; Insulin-Secreting Cells - metabolism; Internal Medicine; Kidney - drug effects; Kidney - metabolism; Male; Medical Microbiology; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Muscle, Skeletal - drug effects; Muscle, Skeletal - metabolism; Original; original-article; Pharmacology/Toxicology; Rats; Rats, Wistar; Sodium-Glucose Transporter 1 - metabolism; Sodium-Glucose Transporter 2 - metabolism; Sodium-Glucose Transporter 2 Inhibitors; Vaccine; 功效; 动物模型; 协同; 肾脏; 脱氧葡萄糖; 转运蛋白; 选择性抑制剂; 降糖; blood glucose; insulin sensitivity; sodium glucose cotransporter 2 (SGLT2); dapagliflozin; type 2 diabetes mellitus; SHR3824; β-cell function
• ISSN: 1671-4083; 1745-7254
• DOI: 10.1038/aps.2013.196

Aim： The sodium glucose cotransporter 2 （SGLT2） plays an Jmportant role in renal glucose reabsorption, thus serves as a new target for the treatment of diabetes. The purpose of this study was to evaluate SHR3824 as a novel selective SGLT2 inhibitor and to characterize its in vivo effects on glucose homeostasis. The effects of chronic administration of SHR3824 on peripheral insulin sensitivity and pancreatic !5-cell function were also investigated. Methods： The in vitro potency and selectivity of SHR3824 were assessed in HEK293 cells transfected with human SGLT2 or SGLTI. Acute and multi-dose studies were performed on ICR mice, GK rats and db/db mice to assess the ability of SHR3824 to enhance urinary glucose excretion and improve blood glucose levels. 2-Deoxyglucose uptake and insulin immunohistochemical staining were performed in the soleus muscle and pancreas, respectively, of db/db mice. A selective SGLT2 inhibitor BMS512148 （dapagliflozin） was taken as positive control. Results： SHR3824 potently inhibited human SGLT2 in vitro, but exerted much weak inhibition on human SGLT1 （the IC50 values of SHR3824 against human SGLT2 and SGLT1 were 2.38 and 4324 nmol/L, respectively）. Acute oral administration of SHR3824 （0.3, 1.0, 3.0 mg/kg） dose-dependently improved glucose tolerance in ICR mice, and reduced hyperglycemia by increasing urinary glucose excretion in GK rats and db/db mice. Chronic oral administration of SHR3824 （0.3, 1.0, 3.0 mg·kg·d-1） dose-dependently reduced blood glucose and HbAlc levels in GK rats and db/db mice, and significantly increased insulin-stimulated glucose uptake in the soleus muscles and enhanced insulin staining in the islet cells of db/db mice. Conclusion： SHR3824 is a potent and selective SGLT2 inhibitor and exhibits antidiabetic efficacy in several rodent models, suggesting its potential as a new therapeutic agent for the treatment of type 2 diabetes.